浙江省金华市人民政府办公室


关于印发金华市人民政府办理人大代表建议

金政办发〔2010〕15号


各县（市、区）人民政府，市政府各部门：
《金华市人民政府办理人大代表建议和政协提案工作规则》已经市政府第103次常务会议研究同意，现印发给你们，请按照执行。


金华市人民政府办公室
二○一○年四月七日　　　　



金华市人民政府办理人大代表
建议和政协提案工作规则

第一章 总 则

　　第一条 为加强和规范政府系统办理人大代表建议、批评、意见（以下简称建议）和政协提案(以下简称提案)工作，提高办理工作质量，根据有关法律、法规和规定，结合我市实际，制定本规则。
　　第二条 人大代表提出建议，是宪法和法律赋予代表的一项重要权利。政协提案是政协履行政治协商、民主监督、参政议政职能的重要方式。认真办理人大代表建议、政协提案，自觉接受人大法律监督和政协民主监督，是政府及其组成部门必须履行的法定职责，也是改进工作作风、实现决策民主化、科学化的有效途径。
　　第三条 市政府各部门、市直各企事业单位、省垂直管理部门、省属驻金单位和县（市、区）政府办理建议、提案工作适用本规则。

第二章 办理范围和职责

第四条 办理建议、提案的范围：
　　（一）市人大代表和在金的全国、省人大代表（以下简称建议人），在市人民代表大会及闭会期间书面提出的，经市人民代表大会秘书处或市人大常委会工作机构交市政府及所属部门研究办理的建议；
　　（二）市政协委员和在金的全国、省政协委员，参加市政协的党派、人民团体和市政协各专门委员会(以下简称提案人)在市政协全体会议及闭会期间书面提出的，经提案审查委员会或提案委员会审查立案后,交市政府及所属部门研究办理的提案；
　　（三）上级政府交办的建议、提案。
　　第五条　市政府系统办理建议、提案工作在市长领导下，由常务副市长分管。市政府办公室是市政府系统办理建议、提案工作的综合协调部门，主要职责：
　　（一）贯彻落实上级有关建议和提案办理工作的政策和规定，研究制定建议和提案办理的工作制度；
　　（二）负责市政府系统建议、提案办理的组织、指导和督促检查工作，协调处理建议、提案办理过程中的问题；
　　（三）会同市人大常委会代表与选举任免工作委员会、市政协提案委员会提出需重点办理的建议、提案，督促承办单位抓好办理落实；
　　（四）办理必须由市政府或市政府办公室办理的建议、提案；
　　（五）加强与市人大常委会代表与选举任免工作委员会、市政协提案委员会、各承办单位及建议人和提案人的联系，听取建议人、提案人对办理工作的意见；
　　（六）组织承办单位总结办理工作，交流和推广办理经验；
　　（七）开展业务培训，提高办理人员的政策水平和业务素质；
　　（八）做好市政府向市人大常委会、市政协报告年度建议、提案办理情况的相关工作。
　　第六条　各承办单位应确定1名领导分管建议、提案办理工作，落实建议、提案办理工作机构和人员，制定本单位建议、提案办理工作制度，认真做好办理工作；主动走访建议人、提案人，听取对办理工作的意见、建议；按期向交办单位报送办理进度，做好办理工作总结。

第三章 办理原则


　　
第七条 依法办理原则。各承办单位应严格遵守国家的法律、法规及党和政府的方针政策，充分尊重建议人、提案人的民主权利，主动接受建议人、提案人的监督，并按照法定程序开展办理工作。
　　第八条 实事求是原则。办理工作要从实际出发，虚心接受建议人、提案人的意见和批评，积极吸取合理化建议，认真研究解决建议、提案提出的问题。凡是应该并有条件解决的，必须马上解决；因条件限制，一时无法解决的，应纳入计划，积极创造条件，逐步予以解决；确因现行法律、法规和政策不许可，或受其它条件限制，目前不能解决的，也要说明情况、解释原因。
　　第九条 求真务实原则。办理建议、提案，应讲实话、办实事、求实效。各承办单位要紧紧围绕市委、市政府中心工作，重点解决事关经济社会发展全局的问题、社会各界普遍关注的热点难点问题和群众最关心、最直接、最现实的利益问题，努力让建议人、提案人满意，让群众受益。

第四章 办理程序


　　
　　第十条 交办。
　　（一）市人民代表大会和市政协全体会议期间提出的建议、提案，经市人大常委会代表与选举任免工作委员会、市政府办公室、市政协提案委员会协商确定承办单位，属政府职权范围内的建议、提案由市政府办公室统一交办。
　　（二）需要在市人民代表大会和市政协全体会议期间办理的建议、提案，分别经市人民代表大会工作机构、市政协提案工作机构研究，交有关部门在会议期间当面答复建议人、提案人。
　　（三）市人民代表大会和市政协全体会议闭会期间提出的建议、提案，由市人大常委会代表与选举任免工作委员会、市政协提案委员会直接交有关部门办理。
　　（四）承办单位接到建议、提案后，应及时清点和核对建议、提案。不属于本单位职责范围，需变更主办单位或增减会办单位的，在收到之日起7个工作日内，书面向市政府督查室说明情况、提出调整意见，由市政府办公室会同市人大常委会代表与选举任免工作委员会、市政协提案委员会研究核实后再作相应调整。承办单位不得滞留、延误和自行转送其它单位。调整期限过后，原则上不再作调整。
上级政府交办的建议、提案，由市政府办公室分解后，交由各承办单位办理。
　　（五）各承办单位接到交办的建议和提案后，应在7个工作日内完成内部交办，明确办理部门和责任。
　　第十一条 承办。
　　（一）承办单位接收建议、提案后，应逐件进行研究分析，联系本单位实际，制定办理方案，明确办理计划、进度安排和工作要求，办理工作量较大的单位应召开交办会，将办理任务落实到具体承办处室和工作人员。
　　（二）承办单位办理的每一件建议、提案，在正式答复前必须与领衔建议人或提案人进行面商沟通，主动听取建议人、提案人对办理工作的意见。建议、提案涉及的问题与法律、政策不符，或超出职权范围的，应向建议人、提案人解释原因。列为重点建议、重点提案和党派团体提案的，应由承办单位主要负责人与建议人、提案人进行面商。
面商可采取上门走访及召开座谈会、研讨会、现场会等多种形式。
　　（三）多家单位共同办理建议、提案的，相关单位应加强配合。主办单位应主动与会办单位联系、协商；会办单位应协同主办单位研究办理，共同参加与建议人、提案人的面商、座谈等，及时提出会办意见，并由主办单位统一答复。各承办单位办理意见不一致时，应由主办单位负责协调。需两家以上单位分别主办的建议、提案，承办单位应依照各自职责办理，并分别答复建议人、提案人。
　　第十二条 审核。
　　承办单位给建议人、提案人的书面答复，由单位具体承办处室负责人把关后送分管领导审核，由单位主要领导审定签发。承办单位应逐件核查内容，认真修改答复意见，着重审核该解决的问题是否已经解决，答复是否符合有关法律、法规和政策规定，格式是否规范，文字是否简明流畅。建议、提案及答复内容涉及国家秘密的，承办单位应做好保密工作。
　　第十三条 答复。
　　（一）市人民代表大会和市政协全体会议期间提出的建议、提案，主办单位应在交办会后3个月内办复（市人大常委会、市政协确定的重点建议、重点提案除外），会办单位应在交办会后1个月内将会办意见书面告知主办单位。因情况特殊，在规定时限内难以完成的，须提前向市政府办公室、市人大常委会代表与选举任免工作委员会或市政协提案委员会提出延期申请，说明理由，经上述单位同意后，办理时限可适当延期。其中，会办件延期时间不得超过1个月，主办件延期时间不得超过3个月。建议人、提案人闭会期间提出的建议、提案，应在3个月内办复，最迟必须在下一次市人民代表大会、政协全体会议召开之前办复。
上级政府交办的建议、提案，按市政府办公室交办通知要求办理。
　　（二）向建议人、提案人答复建议、提案，直接以承办单位名义行文，不得以下属单位或内设机构名义答复。答复件应直接寄送建议人、提案人；联名提出的，应一一抄送附议人。同时，抄送市政府办公室、市人大常委会代表与选举任免工作委员会或市政协提案委员会、代表所在地人大常委会。多家单位共同办理的建议、提案，主办单位应将答复件抄送会办单位。答复建议人或提案人时，应随寄征询意见表。对联名提出的建议、提案，征询意见表只需寄送给建议、提案的领衔人。
　　（三）答复建议、提案应表达准确，文字简洁，用语谦逊，具有针对性。行文按公文处理规定的程序和格式。答复件首页右上角标明分类标识。即：“A”（所提问题已经解决或基本解决的）、“B”（所提问题部分解决或已列入计划解决的）、“C”（所提问题因受条件限制留作参考或不可行的）。答复件附注处应注明联系人姓名、联系电话。
　　（四）由市政府办公室转办的全国、省人大代表建议和全国、省政协提案，承办单位应在规定期限内将办理意见报送市政府办公室，由市政府办公室综合汇总，经市政府领导审定后答复建议人、提案人或交办单位，各承办单位不得自行答复建议人或提案人。
　　第十四条 跟踪督查。
　　每年10月至12月底，主办单位应开展建议、提案办理工作 “回头看”， 认真兑现答复承诺事项，列入计划逐步解决事项应制定明确的落实计划和当年工作目标，并抓好工作落实。往年承办建议、提案未落实事项，也应跟踪办理。每年年底，由市政府办公室会同市人大常委会代表与选举任免工作委员会、市政协提案委员会对重点建议、重点提案落实情况进行跟踪督查。
　　第十五条 办理总结。
　　承办单位建议、提案办理工作结束后，应及时开展办理工作总结，并向市政府办公室、市人大常委会代表与选举任免工作委员会或市政协提案委员会报送书面材料。总结内容包括办理工作的基本情况、主要做法和体会，主要问题处理情况，采纳建议人或提案人建议改进工作的情况，办理取得的成效和产生的社会效应、存在问题及改进措施等。

　　第五章 办理制度



　　第十六条 市政府领导领办重点建议、重点提案制度。根据市人大常委会、市政协确定的重点建议、重点提案，市政府办公室在10个工作日内报请市政府领导，由市政府领导从中选择确定领办件，并成立由市政府领导牵头，主办单位主要领导负总责，主办、会办单位分管领导及责任处室负责人参加的办理工作小组，组织开展办理工作。办理意见由市政府办公室审核并经市政府领导审签后，正式答复建议人、提案人，同时抄送相关单位。
　　第十七条 办理督办制度。市政府办公室应会同市人大常委会代表与选举任免工作委员会、市政协提案委员会，采用电话询问、下发催办督查通知单、上门检查等形式，及时掌握承办单位的办理情况，协助市人大常委会、市政协做好办理视察和评议工作。
　　第十八条 联系沟通制度。各承办单位应加强同建议人、提案人的联系沟通，采取“请进来、走出去”的方式，邀请建议人、提案人开展座谈交流、现场办理，并征求办理意见。
　　第十九条 不满意件重新办理制度。建议人、提案人对建议、提案办理工作表示不满意的，承办单位收到反馈意见后，应由主要领导亲自过问，提出指导意见重新办理。承办单位或具体承办处室负责人应与提出不满意意见的建议人或提案人见面沟通，直接听取和交换意见，制定并落实改进措施。收到不满意意见1个月内，承办单位应再次作出书面答复。

第六章 奖 惩



　　第二十条 市政府办公室会同市委办公室、市人大常委会办公室、市政协办公室，每五年组织一次建议、提案办理工作先进单位评选活动，每年组织一次优秀承办件、办理工作先进个人评选活动。对办理工作成效显著的承办单位和承办人员，应予以表彰。对推诿扯皮、敷衍塞责的单位、个人，应予以通报批评，并责令改正；情节严重的，应追究承办单位负责人的责任。


第七章 附 则

　　 第二十一条 建议、提案办理工作列入市政府各部门工作目标责任制考核范围，重点考核承办单位的问题解决率（所提建议的采纳落实率）、按时办结率、面商率、满意率等。
　　 第二十二条 本规则由市政府办公室负责解释，自发文之日起施行。以往规定与本规则不符的，以本规则为准。



State Food and Drug Administration，State Administration for Industry and Commerceof the People’s Republic of China


Provisions for Drug Advertisement Examination



(SFDA Decree No. 27)

The Provisions for Drug Advertisement Examination, adopted by the State Food and Drug Administration and the State Administration for Industry and Commerce of the People’s Republic of China, is now issued in the decree sequence number of the State Food and Drug Administration. The Provisions shall go into effect as of the date of May 1, 2007.



Shao Mingli
Commissioner
State Food and Drug Administration

Zhou Bohua
Minister
State Administration for Industry and Commerceof the People’s Republic of China

March 13, 2007





Provisions for Drug Advertisement Examination


Article 1 The Provisions are formulated for the purposes of strengthening regulation on drug advertisements and ensuring the authenticity and legality of drug advertisements in accordance with the Advertisement Law of the People’s Republic of China (hereinafter referred to as Advertisement Law), the Drug Administration Law of the People's Republic of China (hereinafter referred to as Drug Administration Law), the Regulations for the Implementation of Drug Administration Law of the People's Republic of China (hereinafter referred to as Regulations for the Implementation of Drug Administration Law) and other regulations related to supervision on advertisements and drugs.

Article 2 A drug advertisement refers to any advertisement published through various media or forms containing drug name, indications (functions) or other relevant contents, and shall be examined and approved in accordance with the Provisions.

Where only the names of non-prescription drugs (including adopted names and trade names) are publicized or only the names of prescription drugs (including adopted names and trade names) are publicized in professional medical or pharmaceutical journals, the examination is not required.

Article 3 The drug advertisement applied for examination shall be approved provided that it conforms to the following laws, regulations and related provisions:
(1) Advertisement Law;
(2) Drug Administration Law;
(3) Regulations for Implementation of Drug Administration Law;
(4) Criteria for Examining and Publishing Drug Advertisement;
(5) Other provisions of the State on advertisement regulation.

Article 4 The drug regulatory departments of the provinces, autonomous regions or municipalities directly under the Central Government are the drug advertisement examination authorities responsible for examining drug advertisements within their administrative regions. The administrative departments for industry and commerce at or above the county level are supervision and control authorities for drug advertisements.

Article 5 The State Food and Drug Administration shall guide and supervise the examination conducted by drug advertisement examination authorities and punish, in accordance with law, the examination authorities that have violated the Provisions.

Article 6 An applicant for a drug advertisement approval number must be an eligible drug manufacturer or distributor. Where the applicant is a drug distributor, the consent of the drug manufacturer is required.

An applicant may entrust an agent with the application for a drug advertisement approval number.

Article 7 An application for a drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the drug manufacturer is located.

An application for an import drug advertisement approval number shall be submitted to the drug advertisement examination authority in the place where the agent of the import drug is located.

Article 8 Where a drug manufacturer or distributor applies for a drug advertisement approval number, it shall submit an Application Form for Drug Advertisement (Appendix 1) with sample manuscript (sample film or sample record) of which the content is consistent with that to be published attached, and an electronic document of drug advertisement application. It shall also submit the following proof documents that are authentic, legal and valid:
(1) Copy of the Business License of the applicant;
(2) Copy of the Drug Manufacturing Certificate or the Drug Supply Certificate of the applicant;
(3) Where the applicant is a drug distributor, the original document proving that the drug manufacturer authorizes the drug distributor to be the applicant shall be submitted;
(4) Where an agent submits an application for a drug advertisement approval number on behalf of the applicant, an original authorization letter given by the applicant to the agent, a copy of business license of the agent and other documents proving the subject’s qualifications shall be submitted;
(5) Copies of the drug approval document (including Import Drug License or Pharmaceutical Product License), copy of approved insert sheet, and label and insert sheet used in practice;
(6) For non-prescription drug advertisement, a copy of registration certificate of non-prescription drug examination or copies of relevant certificates is required;
(7) Where an applicant applies for an import drug advertisement approval number, copies of qualification certificates of the agent of the import drug shall be submitted;
(8) Where the trade name, registered trademark and patent of the drug are involved in an advertisement, copies of the valid certificates and other relevant documents proving the authenticity of the advertisement shall be submitted.

The copy of any approval document prescribed in this Article shall be sealed by the document holder.

Article 9 An advertisement application by an enterprise for a drug shall not be accepted by the drug advertisement examination authorities under any of the following circumstances:
(1) Any of the circumstances under which the application shall be rejected as prescribed in Article 20, Article 22 and Article 23 of the Provisions;
(2) An administrative procedure to withdraw a drug advertisement approval number is in process.

Article 10 After receiving an application for drug advertisement approval number, where the dossier is complete and in conformity with statutory requirements, the drug advertisement examination authority shall issue an Acceptance Notice of Drug Advertisement; where the dossier is incomplete or not conforming to the statutory requirements, one notification on all the content to be supplemented or corrected shall be given to the applicant on the spot or within five working days; if the notification to the applicant is not issued within the timeline, the application is deemed as being accepted upon the date when the dossier is received.

Article 11 Within ten working days upon accepting an application, the drug advertisement examination authority shall check the authenticity, legality and validity of the documents submitted by the applicant, and shall examine the advertisement content in accordance with law. For the drug advertisement in conformity with statutory requirements, a drug advertisement approval number shall be issued; for those not in conformity with statutory requirements, the authority shall make a decision of not issuing a drug advertisement approval number and notify the applicant of the decision with reasons in written form and the applicant’s right to apply for administrative reconsideration or to bring an administrative suit by law.

For approved drug advertisement, the drug advertisement examination authority shall report to the State Food and Drug Administration for records and send the approved Application Form for Drug Advertisement to the authority responsible for advertisement supervision and control at the same level for records. Where there is any problem in the drug advertisement reported to the State Food and Drug Administration for records, the State Food and Drug Administration shall instruct the drug advertisement examination authority to correct it.

The drug regulatory departments shall announce the approved drug advertisement timely.

Article 12 Where a drug advertisement is to be published in the province, autonomous region or municipality directly under the Central Government other than the place where the drug manufacturer and the agent of the import drug are located (hereinafter referred to as “non-local drug advertisement”), it shall, before being published, be submitted for records to the drug advertisement examination authority in the place where the advertisement is to be published.

Article 13 The following materials for non-local drug advertisement shall be submitted for record:
(1) Copy of the Application Form for Drug Advertisement;
(2) Copy of the approved drug insert sheet;
(3) For television or audio broadcast advertisement, it is required to submit the audio tape, compact disc or other medium carrier on which the content is consistent with the approved content.

The copy of any document prescribed in this Article shall be sealed by the document holder.

Article 14 For application for putting non-local drug advertisement on record in accordance with Articles 12 and Article 13 of the Provisions, the drug advertisement examination authority shall, within five working days after accepting the application, put such drug advertisement on record, endorse the word “recorded” on the Application Form for Drug Advertisement, affix the seal specific for drug advertisement examination and send the form to the supervision and control authorities for advertisements at the same level for future reference.

Where the drug advertisement examination authority of a place where a drug advertisement is to be put on record finds that the drug advertisement is not conformed with the relevant provisions, it shall fill in the Opinion on the Record of Drug Advertisement Examination (Appendix 2), submit it to the original drug advertisement examination authority for check, and copy it to the State Food and Drug Administration.

Within five working days upon receiving the Opinion on the Record of Drug Advertisement Examination, the original drug advertisement examination authority shall give its opinions to the drug advertisement examination authority of the place where the drug advertisement is to be put on record. Where no consensus is achieved between the original drug advertisement examination authority and the drug advertisement examination authority of the place where a drug advertisement is to be put on record, the case may be submitted to the State Food and Drug Administration that shall make a final judgment.

Article 15 The valid term of a drug advertisement approval number is one year. It shall become invalid upon expiration.

Article 16 The content of an approved drug advertisement is not allowed to be changed when being published. Where any change to the drug advertisement is needed, a new drug advertisement approval number shall be obtained.

Article 17 Where an advertisement applicant publishes a drug advertisement by itself, it shall keep the original Application Form for Drug Advertisement for two years for future check.

Where an advertisement publisher or advertising operator is authorized by the applicant to publish a drug advertisement, it shall check the original Application Form for Drug Advertisement, publish the advertisement in accordance with the approved content and keep a copy of the Applicant Form for Drug Advertisement for two years for future check.

Article 18 Where there is any of the following circumstances for an approved drug advertisement, the original drug advertisement examination authority shall issue a Notice of Drug Advertisement Re-examination (Appendix 3) and conduct the re-examination. The drug advertisement may continue to be published during the re-examination.

(1) The State Food and Drug Administration finds that the content of the drug advertisement approved by the drug advertisement examination authority is not in conformity with the provisions;
(2) A supervision and control authority for advertisement at or above provincial level makes a re-examination proposal;
(3) Other circumstances where a re-examination is required by a drug advertisement examination authority.

After re-examination, where the drug advertisement is not in conformity to the statutory requirements, the Application Form for Drug Advertisement shall be taken back and the original drug advertisement approval number shall become invalid.

Article 19 Drug advertisement examination authorities shall cancel the drug advertisement approval number in any of the following circumstances:
(1) Where a Drug Manufacturing Certificate or the Drug Supply Certificate is revoked;
(2) Where a drug approval document is withdrawn or cancelled;
(3) Where the State Food and Drug Administration or the drug regulatory department of the province, autonomous region or municipality directly under the Central Government instructs to stop the production, sales and use of the drug.

Article 20 For any alteration to the approved content of a drug advertisement for false propaganda, the drug regulatory departments shall instruct to stop the publication of the advertisement immediately, revoke the drug advertisement approval number, and shall not accept any application for advertisement of the drug within one year.

Article 21 Where any illegal advertisement in which the scope of indications (functions) of the drug is expanded without authorization, the therapeutic effectiveness is exaggerated extremely, or which seriously cheats or misleads the customers, is found, the drug regulatory department at or above the provincial level shall take mandatory administrative measures to suspend the sales of the drug within their administrative area and order the enterprise that illegally publishes the drug advertisement to issue a correction notice in relevant local media.

After the enterprise that illegally publishes the drug advertisement issues a correction notice as required, the drug regulatory department at or above the provincial level shall make a decision on lifting the mandatory administrative measures within 15 working days; where it is necessary to test the drug, the drug regulatory departments shall determine whether to lift the mandatory administrative measures within 15 days as from the day when the test report is issued.

Article 22 Where a drug advertisement application providing false materials is found by the drug advertisement examination authority during the examination, no further application of the enterprise in respect of the advertisement of the drug shall be accepted within one year.

Article 23 Where a drug advertisement with an approval number is found by the drug advertisement examination authority to have provided false materials, such drug advertisement approval number shall be revoked and no further application from the enterprise in respect of the advertisement of the drug shall be accepted within three years.

Article 24 Any drug advertisement, of which the approval number is taken back, cancelled or revoked in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, shall be discontinued for publication immediately; non-local drug advertisement examination authorities shall stop filing the record of the advertisement of the enterprise with the drug advertisement approval number.

Where a drug advertisement examination authority takes back, cancels or withdraws a drug advertisement approval number in accordance with Article 18, Article 19, Article 20 and Article 23 of the Provisions, it shall notify the supervision and control authority for advertisements at the same level within five working days from the day when the administrative decision on the matter is made; the supervision and control authority for advertisements shall handle it in accordance with law.

Article 25 Where a non-local drug advertisement is found not put on record in the drug advertisement examination authority of the place where it is published, the authority shall instruct to file its record within a time limit. If the record is not filed within the time limit, the drug advertisement in the above-mentioned place shall be suspended.

Article 26 The drug regulatory department at or above the county level shall monitor and check the publishing of drug advertisement that has been examined and approved. For any illegal drug advertisements, drug regulatory departments at all levels shall fill in the Notice on the Transfer of Illegal Drug Advertisement (Appendix 4) and transfer it to an supervision and control authority for advertisements at the same level together with such materials as samples of illegal drug advertisement; where the content of approved non-local drug advertisement is altered without permission, the drug advertisement examination authority of the place where the advertisement is published shall advise the original drug advertisement examination authority to revoke its approval number in accordance with Article 92 of the Drug Administration Law and Article 20 of the Provisions.

Article 27 Where an illegal drug advertisement is published and the circumstances are serious, the drug regulatory department of province, autonomous region or municipality directly under the Central Government shall announce the matter to the public and timely report it to the State Food and Drug Administration. The State Food and Drug Administration shall summarize and release the collected information periodically.

Where any false or illegal drug advertisement is published and the circumstances are serious, it shall be announced to the public jointly by the State Administration for Industry and Commerce and the State Food and Drug Administration if necessary.

Article 28 For any drug advertisement published without approval, or the contents published inconsistent with the approved ones, the supervision and control authority for advertisements shall impose a punishment in accordance with Article 43 of the Advertisement Law; where it constitutes false advertisement or misleading propaganda, the supervision and control authorities for advertisements shall impose a punishment in accordance with Article 37 of the Advertisement Law and Article 24 of Anti-Unfair Competitions Law.

In the process of investigation of an illegal drug advertisement, where there is a need to affirm any drug technical information, the supervision and control authority for advertisements shall notify the drug regulatory department at or above the provincial level. The drug regulatory department at or above the provincial level shall give the affirmation result to the supervision and control authorities for advertisements within ten working days after receiving the notification.

Article 29 The staff members that examine and supervise drug advertisements shall be trained in such laws and regulations as the Advertisement Law and the Drug Administration Law. Where the staff members in drug advertisement examination department or in supervision and control authority for drug advertisements neglect their duty, abuse their power, or practice favoritism and commit irregularities, they shall be given an administrative sanction in accordance with law. If a crime is constituted, they shall be investigated for their criminal liabilities in accordance with law.

Article 30 A drug advertisement approval number shall be “X Yao Guang Shen (Shi) No. 0000000000", “X Yao Guang Shen (Sheng) No. 0000000000", “X Yao Guang Shen (Wen) No. 0000000000". “X” is the abbreviation for a province, autonomous region or municipality directly under the Central Government. “0000000000” is a number with ten digits, in which the first six represent year and month of the examination, and the last four represent advertisement approval sequence number. “Shi”, “Sheng” or “Wen” represents certain classification code used in advertising media.

Article 31 These Provisions shall come into force as of May 1, 2007. The Provisions for Drug Advertisement Examination issued by the State Administration for Industry and Commerce and the Ministry of Health (Decree of State Administration for Industry and Commerce No. 25) on March 22, 1995 shall be annulled therefrom.